EZH2 is a potential therapeutic target for H3K27M mutant paediatric gliomas
ChIP-seq / ATAC-seq (genome binding and open chromatin) · mouse · 38 samples
- What it is
- ChIP-seq / ATAC-seq (genome binding and open chromatin)Where proteins bind the genome, or which regions are open and active.
- Organism
- Mus musculus (mouse)
- Samples
- 38 samples: 32 distinct titles, 4 of them repeatedGroups are read from the sample names, not from the paper. Check the list below.
- Data you can get
- A processed table (series matrix) and supplementary files from NCBI; the raw sequencing reads from ENA. Which of these hold counts depends on the study, so check the file list.
Direct links to NCBI and ENA, no account and no request form. Pick by what you want to do: take the small processed table to look, the supplementary files to re-analyse, or the original raw data to start over.
Processed table
The series matrix: one table of values per sample as the submitters processed it. The smallest download, and it opens in Excel or R. Start here to see what the data look like.
Supplementary files
The count tables and other files the authors uploaded. Take only the samples you need, or the whole study as GSE85390_RAW.tar (it can run to tens of gigabytes).
Raw sequencing reads
The original FASTQ files, straight from the sequencer, held at ENA. Large, and you align them yourself, so only choose this if you need to re-process the study from scratch.
What the files usually look like: Look for peak files (.bed, .narrowPeak) and signal tracks (.bigWig) among the supplementary files; the raw reads are on ENA.
Also filed as BioProject PRJNA338311 and SRA study SRP081168. Searching any of these in the dataset finder brings you back here.
How we read this: Read from 38 sample titles: 32 distinct titles with little repetition. These groups are guessed from the sample names, not taken from the paper, so check them against the sample list below before relying on them.
- GSM2266103 PDGFB H3 DMSO I
- GSM2266104 PDGFB H3 DMSO II
- GSM2266105 PDGFB H3 DMSO III
- GSM2266106 PDGB K27M DMSO I
- GSM2266107 PDGFB K27M DMSO II
- GSM2266108 PDGFB K27M DMSO III
- GSM2266109 PDGFB H3 EPZ I
- GSM2266110 PDGFB H3 EPZ II
- GSM2266111 PDGFB H3 EPZ III
- GSM2266112 PDGFB K27M EPZ I
- GSM2266113 PDGFB K27M EPZ II
- GSM2266114 PDGFB K27M EPZ III
- GSM2266115 PDGF H3.3 me3 rep1
- GSM2266116 PDGF K27M me3 rep1
- GSM2266117 PDGF H3.3 EPZ me3 rep1
- GSM2266118 PDGF K27M EPZ me3 rep1
- GSM2266119 PDGF H3.3 IgG rep1
- GSM2266120 PDGF H3.3 DMSO me3 rep2
- GSM2266121 PDGF K27M me3 rep2
- GSM2266122 PDGF H3.3 EPZ me3 rep2
- GSM2266123 PDGF K27M EPZ me3 rep2
- GSM2266124 PDGF H3.3 DMSO IgG rep2
- GSM2266125 PDGF H3.3 Ring1b
- GSM2266126 PDGF K27M Ring1b
- GSM2266127 PDGF H3.3 Suz12
- GSM2266128 PDGF K27M Suz12
- GSM2266129 DIPG007 DMSO me3
- GSM2266130 DIPG007 DMSO IgG
- GSM2266131 DIPG012 DMSO me3
- GSM2266132 DIPG012 DMSO IgG
- GSM2266133 SF7761 DMSO me3
- GSM2266134 SF7761 DMSO IgG
- GSM2266135 SF8628 DMSO me3
- GSM2266136 SF8628 DMSO IgG
- GSM2266137 PDGFB K27M T3
- GSM2266138 PDGFB K27M T2
- GSM2266139 PDGFB K27M T1
- GSM2266140 PDGFB K27M T4
- GSE294966 ChIP-seq for beta-catenin, EZH2, EED, KMT2B, H3K4me3, H3K27me3 and sequential chipseq 148 samples shares h3k27m, ezh2
- GSE218715 EZH2 gain-of-function mutations distort H3K27me3 landscapes and transform transcriptional responses to PRC2 inhibition [RNA-seq] 88 samples shares h3k27m, ezh2
- GSE303627 MYST acetyltransferases are a targetable therapeutic vulnerability in SETBP1-mutant leukemia [CUT&Run] 46 samples shares therapeutic, target, mutant
- GSE209813 DHODH is an independent prognostic marker and potent therapeutic target in neuroblastoma 34 samples shares therapeutic, target
- GSE283532 MOZ and HBO1 Histone Acetyltransferase Complexes Are Molecular Dependencies and Therapeutic Targets in NUP98-Rearranged Acute Myeloid Leukemia 70 samples shares therapeutic, target
- GSE298719 A Human Single-cell Atlas Identifies OLR1+ Scar-associated Macrophages as a Therapeutic Target for Chronic Liver Disease 41 samples shares therapeutic, target
- GSE29799 RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukemia 30 samples shares therapeutic, target
- GSE209812 DHODH is an independent prognostic marker and potent therapeutic target in neuroblastoma [RNA-seq] 27 samples shares therapeutic, target
Metadata from NCBI GEO, cached and refreshed periodically — the NCBI page above is authoritative. Downloads link straight to NCBI/ENA; nothing is proxied through BioTransfer.